Literature DB >> 25022408

MALT lymphoma at the base of tongue of a 29-year-old woman treated with radiation therapy alone.

Jin Ho Song, Dong Il Sun, Young Seon Hong, Gyeong Sin Park, Yeon Sil Kim1.   

Abstract

Mucosa-associated lymphoid tissue (MALT) lymphoma is frequently reported in the gastrointestinal tract (GIT), but the incidence is low in the upper aerodigestive tract. In particular, MALT lymphoma of the tongue is very rare. Only four cases have been reported in the English literature to date. We report a case of 29-year-old woman who had a past history of peripheral T cell lymphoma of the head and neck and a new mass at the right base of tongue 3 years later. An incisional biopsy of the base of tongue revealed a new pathology, one that of extranodal marginal zone B cell lymphoma (MALT lymphoma). After staging work-up, she was diagnosed to be at the Ann Arbor stage IE. She was treated with 30.6 Gy of radiation therapy alone and there was no recurrence after 3 years follow-up.

Entities:  

Mesh:

Year:  2014        PMID: 25022408     DOI: 10.4103/0973-1482.136673

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  4 in total

1.  MALT lymphoma of the base of the tongue: a rare case entity.

Authors:  Haissan Iftikhar; Moghira Iqbaluddin Siddiqui; Khurram Minhas
Journal:  BMJ Case Rep       Date:  2016-02-24

2.  Extranodal lymphoma of the tongue, a very rare entity-report of two cases with literature review.

Authors:  J Clarke; S Medford; S Islam; C Ramsingh; M Christopher
Journal:  Int J Surg Case Rep       Date:  2018-11-30

3.  Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report.

Authors:  Hilal Hafian; Hubert Schvartz; Martine Patey; Anne Quinquenel
Journal:  BMC Oral Health       Date:  2021-11-23       Impact factor: 2.757

4.  Valproic Acid Inhibits Peripheral T Cell Lymphoma Cells Behaviors via Restraining PI3K/AKT Pathway.

Authors:  Zhiqiang Peng; Jianping Xiong; Hanzhi Dong
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-05       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.